Skip to main content
Equibles
PLRX logo

PLRX · Pliant Therapeutics, Inc.

Track PLRX — free

Use PLRX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research PLRX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.93 +0.03 (+3.04%)
Rebalance outlook locked
Market Cap
$55.65M
Shares
61.92M
Volume · Oct 20 319.34K Avg daily vol (3M) 421.64K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$0.91 Open$0.90 Day$0.90–0.94 52W close$0.88–1.87 Avg vol 30d398K Short int4.2M · 6.9% float · 11.4d Short vol41% DataJun 2020–Oct 2026 Filing10-Q · Aug 11

Up next

Latest filing: 10-Q
filed Aug 11, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$0
Trailing 12 months
Net income (TTM)
−$92.29M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-127.2%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$158.10M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.9%
Year over year · more shares
Price change (1Y)
-42.8%
Trailing year
Short interest
6.9%
Latest settlement · 11.4 days to cover
View all 122 metrics

Equibles Rating

blended score · not investment advice
Overall
Strong Sell
SellHoldBuy
Technical Strong Sell Momentum Very Weak Sentiment Bearish Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 18.4 · elevated Equity put/call 0.55
Technical
price trend
Strong Sell
50 / 200-day cross No cross
Price vs 200-day avg −23%
below
Price vs 50-day avg −16%
below
RSI (14) 37
neutral
MACD trend Negative
52-week position 3%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −20%
trailing
6-month return −25%
trailing
YTD return −25%
this year
Relative strength −33%
vs S&P · 6-mo
Sentiment
smart money
Bearish
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
2 of 86 funds reported for Sep 30 · net -174.5K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.86% of float · ▲ +15.0% MoM · 11.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
86 holders — near 3-yr low, contrarian setup
Squeeze score 57
elevated · 0–100
Fundamentals
Strong
EPS growth +30%
Y/Y
Free cash flow $-128.7M
Balance sheet $45.4M
net cash
Quant / Vol
risk profile
Very High
Volatility 51%
annualized · 1-yr
Max drawdown −53%
past year
ATR 5.8%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Strong Sell
4 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−23% Bearish
Price vs 50-day avg
−16% Bearish
RSI (14)
37 Neutral
MACD trend
Negative Bearish
52-week position
3% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $1 › 200d $1 — 200d above 50d
Institutional flow Distributing
2 of 86 funds reported for Sep 30 · net -174.5K sh shares
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
6.86% of float · ▲ +15.0% MoM · 11.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr low
86 holders — near 3-yr low, contrarian setup
Price context
position in its 52-week range
Range low $1 Now $1 · 3% Range high $2
vs 200-day avg -23% vs 50-day avg -16%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PLRX
Pliant Therapeutics, Inc.
this stock
$55.65M -25.2% — — 6.9%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.07B +13.5% +46.2% 29.9 1.8%
MRNA
Moderna, Inc.
 $90.58B +720.9% +4.3% — 7.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $80.51B +4.6% +20.8% 19.4 2.1%
CSLLY
Csl Ltd
 $64.50B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Reducing
Holders
85
% held
77.6%
Reported
2 of 86
Top holder
TANG CAPITAL MANAGEMENT L…
Held Float
View
Held by Funds
Fund positions
31
View
Short & Settlement
Short Interest Rising
Shares short
4.2M
Days to cover
11.4d
Change
+554.1K sh
View
Short Volume
Short vol %
41%
As of
Oct 19, 2026
Short Total
View
Fails to Deliver
FTD shares
73
Value
$84
As of
Sep 10, 2026
View
Off-Exchange
Off-exchange %
24.5%
Week of
Sep 14, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$0
Net income (FY)
$-149.3M
EPS diluted
$-2.43
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 11, 2026
This year
13
View
Proposed Sales
Value
$113.2K
Shares
10.2K
Filed
Jan 22, 2025
View
Exempt Offerings
Offering
$100.4M
Filed
Mar 11, 2020
View
Earnings & Events
Webcasts
Last webcast
May 19, 2026
View

Performance

5D 20D 120D MTD YTD
PLRX -5.7% -20.0% -24.6% -15.5% -25.2%
SPY -1.2% -0.6% +8.1% +0.8% +12.8%
vs SPY -4.6% -19.4% -32.7% -16.4% -38.0%
Key facts CIK 1746473 CUSIP 729139105 13F (30d) 2 filings 2 filers Visit website Investor relations